Tango Therapeutics (TNGX) Projected to Post Earnings on Monday

Tango Therapeutics (NASDAQ:TNGX) will likely be issuing its Q1 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect Tango Therapeutics to post earnings of ($0.34) per share and revenue of $6.73 million for the quarter.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.03). Tango Therapeutics had a negative net margin of 284.42% and a negative return on equity of 49.64%. The business had revenue of $4.12 million during the quarter, compared to analyst estimates of $7.84 million. On average, analysts expect Tango Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tango Therapeutics Stock Up 1.8 %

Shares of NASDAQ TNGX opened at $1.12 on Friday. The company has a market capitalization of $121.08 million, a PE ratio of -0.95 and a beta of 1.02. The firm has a fifty day simple moving average of $1.51 and a 200 day simple moving average of $2.71. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $12.02.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $13.00 price objective on shares of Tango Therapeutics in a research note on Monday, April 14th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tango Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $12.33.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.